Anti-CD30 Antibody (Brentuximab)
Catalog No.
F2102
Anti-CD30 Antibody (Brentuximab)
Featured Products
Brentuximab is an antibody-drug conjugate (ADC) consisting of a monoclonal antibody and an anti-tubulin drug. Its monoclonal antibody is derived from humanized IgG1 and targets the CD30 molecule. It internalizes and releases cytotoxic drugs after binding to CD30, thereby destroying cancer cells. Brentuximab is mainly used to treat Hodgkin's lymphoma and systemic anaplastic large cell lymphoma.
Quality Control & DataSheet
- View current batch:
145.38 kDa
Dry ice
2088770-90-3
-80°C
2 years
Liquid
1 mg/mL
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
Brentuximab Vedotin, Adcetris
100 mM Pro 20 mM Arg pH 5.0.
Chimeric
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
CD30
Please avoid freeze-thaw cycles.